Table 7.

Group D: patients treated with myeloablative protocols

Pat.	Age/sex	Cut. manif.	Extracut. manif.	High-dose chemotherapy±TBI	Source of stem cells	BM/peripheral	Time of Tx	Survival (months)
29	29/m	−	+	HD cyclophosphamide+TBI	Allogeneic	BM	First CR	76+ in CR
35	24/f	+	+	HD cyclophosphamide melphalan+TBI*	Allogeneic	BM	First CR	115+ in CR*
38	35/m	+	−	ND	Allogeneic	BM	Second CR	39 died of sepsis in PD
56	6/f	−	+	Aracytidine, melphalane+TBI*	Allogeneic	BM	First CR	98+ in CR
69	28/m	+	−	HD cyclophosphamide+ TBI*	Allogeneic	BM	First CR	38 AWD relapse at 12 months
80	29/m	+	−	ND	Allogeneic	BM	Third CR	25 died in CR due to ARDS
d	23/m	+	+	Busulfan, thiotepa, fludarabine, ATG − TBI	Allogeneic	Peripheral	Second CR	20 died in CR therapy-related
23	25/m	+	+	HD cyclophosphamide, etoposide+TBI	Autologous	Peripheral	PR after First relapse	71+ in CR*
43	51/m	+	+	HD cyclophosphamide, carboplatin, etoposide, dexamethasone − TBI*	Autologous	Peripheral	First CR	13 PD died of pneumonia
d	23/m	+	+	HD cyclophosphamide+TBI	Autologous	Peripheral	First CR	20 relapse see above
e	32/m	+	+	HD cyclophosphamide+TBI	Autologus	Peripheral	First CR	13 DOD
n=10	Med. 28.5 m:f 8:2	8/10 80%	7/10 70%		allo:auto 7:4**	BM/peripheral 6:5**		Med. OS 31.5 CR at last follow-up 5/10 (50%)

^*Personal communication.

^**Patient d underwent both autologous and allogeneic stem cell transplantion.

Cut. manif: cutaneous manifestations; extracut. manif.=extracutaneous manifestations; ARDS: acute respiratory distress syndrome; ATG: antithymocyte globulin; AWD: alive with disease; BM: bone marrow; DOD: died of disease; HD: high dose; TBI: total body irradiation; Tx: transplantation; CR: complete remission; PR: partial remission; PD: progressive disease; ND: not determined.